Hidayatullah G. Munshi
Affiliations: | Integrated Graduate Program in the Life Sciences | Northwestern University, Evanston, IL |
Area:
General Biology, Cell Biology, Molecular Biology, OncologyGoogle:
"Hidayatullah Munshi"
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Shields MA, Metropulos AE, Spaulding C, et al. (2023) BET inhibition rescues ciliogenesis and ameliorates pancreatitis-driven phenotypic changes in mice with Par3 loss. Biorxiv : the Preprint Server For Biology |
Pham TN, Spaulding C, Shields MA, et al. (2022) Inhibition of MNKs promotes macrophage immunosuppressive phenotype to limit CD8+ T cell antitumor immunity. Jci Insight. 7 |
Shields MA, Spaulding C, Metropulos AE, et al. (2022) Gα13 loss in Kras/Tp53 mouse model of pancreatic tumorigenesis promotes tumors susceptible to rapamycin. Cell Reports. 38: 110441 |
Principe DR, Underwood PW, Kumar S, et al. (2022) Loss of SMAD4 Is Associated With Poor Tumor Immunogenicity and Reduced PD-L1 Expression in Pancreatic Cancer. Frontiers in Oncology. 12: 806963 |
Principe DR, Xiong R, Li Y, et al. (2022) XP-524 is a dual-BET/EP300 inhibitor that represses oncogenic KRAS and potentiates immune checkpoint inhibition in pancreatic cancer. Proceedings of the National Academy of Sciences of the United States of America. 119 |
Kwong AJ, Pham TND, Oelschlager HE, et al. (2021) Rational Design, Optimization, and Biological Evaluation of Novel MEK4 Inhibitors against Pancreatic Adenocarcinoma. Acs Medicinal Chemistry Letters. 12: 1559-1567 |
Pham TND, Shields MA, Spaulding C, et al. (2021) Preclinical Models of Pancreatic Ductal Adenocarcinoma and Their Utility in Immunotherapy Studies. Cancers. 13 |
Pham TND, Spaulding C, Munshi HG. (2020) Controlling TIME: How MNK Kinases Function to Shape Tumor Immunity. Cancers. 12 |
Principe DR, Kamath SD, Munshi HG, et al. (2020) Metastatic Thymoma Harboring a Deleterious BRCA2 Mutation Derives Durable Clinical Benefit from Olaparib. The Oncologist. 25: 301-305 |
Principe DR, Narbutis M, Kumar S, et al. (2020) Long-Term Gemcitabine Treatment Reshapes the Pancreatic Tumor Microenvironment and Sensitizes Murine Carcinoma to Combination Immunotherapy. Cancer Research |